Improving clinical trial interpretation with ACCEPT analyses
Authors:
- Michelle N. ClementsMCMichelle N. Clements
- Ian R. WhiteIWIan R. White
- Andrew J. CopasACAndrew J. Copas
- Victoria CorneliusVCVictoria Cornelius
- Suzie CroSCSuzie Cro
- David T DunnDDDavid T Dunn
- Matteo QuartagnoMQMatteo Quartagno
- Rebecca M. TurnerRTRebecca M. Turner
- Conor D. TweedCTConor D. Tweed
- A. Sarah WalkerAWA. Sarah Walker
Preprint
Abstract
Effective decision making from randomised controlled clinical trials relies on robust interpretation of the numerical results. However, the language we use to describe clinical trials can cause confusion both in trial design and in comparing results across trials. ACceptability Curve Estimation using Probability Above Threshold (ACCEPT) aids comparison between trials (even where of different designs) by harmonising reporting of results, acknowledging different interpretations of the results may be valid in different situations, and moving the focus from comparison to a pre-specified value to interpretation of the trial data. ACCEPT can be applied to historical trials or incorporated into statistical analysis plans for future analyses. An online tool enables ACCEPT on up to three trials simultaneously.Keywords
All Related Versions
This publication has 13 references indexed in Scilit:
- A Trial of a Shorter Regimen for Rifampin-Resistant TuberculosisNew England Journal of Medicine, 2019
- Scientists rise up against statistical significanceNature, 2019
- Oral versus Intravenous Antibiotics for Bone and Joint InfectionNew England Journal of Medicine, 2019
- Effect of Therapeutic Hypothermia Initiated After 6 Hours of Age on Death or Disability Among Newborns With Hypoxic-Ischemic Encephalopathy: A Randomized Clinical TrialObstetrical & Gynecological Survey, 2018
- Assessment of Second-Line Antiretroviral Regimens for HIV Therapy in AfricaNew England Journal of Medicine, 2014
- Ritonavir-boosted lopinavir plus nucleoside or nucleotide reverse transcriptase inhibitors versus ritonavir-boosted lopinavir plus raltegravir for treatment of HIV-1 infection in adults with virological failure of a standard first-line ART regimen (SECOND-LINE): a randomised, open-label, non-inferiority studyThe Lancet, 2013
- Assessing noninferiority in a three‐arm trial using the Bayesian approachStatistics in Medicine, 2011
- Tutorial: Using Confidence Curves in Medical ResearchBiometrical Journal, 2005
- Improving interpretation of clinical studies by use of confidence levels, clinical significance curves, and risk-benefit contoursThe Lancet, 2001
- Bayesian Approach to Bioequivalence Assessment: An ExampleJournal of Pharmaceutical Sciences, 1983